2134-2135 / 2351
• Median survival of patients is 10-12 months (? Immunotherapy)
• First-line: Cisplatin /5-FU/cetuximab: standard of care
• Second-line: nivolumab
• Options: Platin/paclitaxel, taxanes, methotrexate
|
|
2134-2135 / 2351
• Median survival of patients is 10-12 months (? Immunotherapy)
• First-line: Cisplatin /5-FU/cetuximab: standard of care
• Second-line: nivolumab
• Options: Platin/paclitaxel, taxanes, methotrexate